Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence in Southern Province, Zambia: study protocol for a community randomized controlled trial by unknown
TRIALS
Eisele et al. Trials  (2015) 16:347 
DOI 10.1186/s13063-015-0862-3STUDY PROTOCOL Open AccessAssessing the effectiveness of
household-level focal mass drug
administration and community-wide mass
drug administration for reducing malaria
parasite infection prevalence and incidence in
Southern Province, Zambia: study protocol for a
community randomized controlled trial
Thomas P. Eisele1*, Kafula Silumbe2, Timothy Finn1, Victor Chalwe3, Mukalwa Kamuliwo4, Busiku Hamainza4,
Hawela Moonga4, Adam Bennett5, Josh Yukich1, Joseph Keating1, Richard W. Steketee6 and John M. Miller2Abstract
Background: Mass drug administration (MDA) and focal MDA (fMDA) using dihydroartemisinin plus piperaquine
(DHAp), represent two strategies to maximize the use of existing information to achieve greater clearance of
human infection and reduce the parasite reservoir, and provide longer chemoprophylactic protection against new
infections. The primary aim of this study is to quantify the relative effectiveness of MDA and fMDA with DHAp
against no mass treatment (standard of care) for reducing Plasmodium falciparum prevalence and incidence.
Methods/design: The study will be conducted along Lake Kariba in Southern Province, Zambia; an area of low to
moderate malaria transmission and high coverage of vector control. A community randomized controlled trial
(CRCT) of 60 health facility catchment areas (HFCAs) will be used to evaluate the impact of two rounds of MDA and
fMDA interventions, relative to a control of no mass treatment, stratified by high and low transmission. Community
residents in MDA HFCAs will be treated with DHAp at the end of the dry season (round one: November to
December 2014) and the beginning of the rainy season (round two: February to March 2015). Community residents
in fMDA HFCAs will be tested during the same two rounds for malaria parasites with a rapid diagnostic test; all
positive individuals and all individuals living in their household will be treated with DHAp. Primary outcomes
include malaria parasite prevalence (n = 5,640 children aged one month to under five-years-old), as measured by
pre- and post-surveys, and malaria parasite infection incidence (n = 2,250 person-years among individuals aged
three months and older), as measured by a monthly longitudinal cohort. The study is powered to detect
approximately a 50 % relative reduction in these outcomes between each intervention group versus the control.
Discussion: Strengths of this trial include: a robust study design (CRCT); cross-sectional parasite surveys as well as a
longitudinal cohort; and stratification of high and low transmission areas. Primary limitations include: statistical
power to detect only a 50 % reduction in primary outcomes within high and low transmission strata; potential for
contamination; and potential for misclassification of exposure.
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The recent Zambian National Malaria Strategic Plan
2011 to 2016 calls for ambitious efforts to work towards
malaria elimination, with the establishment of at least
five malaria-free zones by 2015 [1]. The Zambian govern-
ment, through its National Malaria Control Centre
(NMCC), has successfully scaled up the main World
Health Organization (WHO)-recommended malaria con-
trol interventions (for example, long-lasting insecticide-
treated mosquito nets (LLINs), indoor residual spraying
(IRS), and prompt effective treatment of malaria) over the
past decade and is considering alternative strategies to
further reduce malaria prevalence and burden [2]. While
recognizing that eliminating malaria from the country
may require many years to achieve, malaria elimination is
a realistic milestone for Zambia in light of recent successes
in reducing the malaria burden through a collaborative ef-
fort among the NMCC and its partners [2].
During the 2012 dry season (June to November) in
Southern Zambia, the effectiveness of three large-scale
malaria mass test and treatment (MTAT) intervention
rounds were assessed with a community randomized
controlled trial (CRCT) [3]. The MTAT intervention con-
sisted of testing all individuals in intervention areas with
rapid diagnostic tests (RDTs); all positive individuals were
treated with artemether-lumefantrine (AL; MTAT-AL),
which is the first-line drug for treating uncomplicated
malaria in Zambia. The MTAT-AL intervention aimed
to reduce community-wide malaria transmission by tar-
geting persons infected with the asexual stage, and
treating both asexual (blood) stage and immature sex-
ual stage (immature gametocytes) infections of the
Plasmodium falciparum parasite, thereby preventing
onward transmission from infected individuals.
The results of the Zambia MTAT trial [3], as well
as those from a recent trial of MTAT-AL in Burkina
Faso [4] and Zanzibar [5], suggest that the use of
MTAT-AL will likely be insufficient to achieve malaria
elimination in many settings, for several important
reasons. The generally short terminal elimination
half-life of AL (less than three days), combined with
the short duration of the treatment regimen (taken
over three days), may provide little chemoprophylactic
or chemo-suppressive protection against reinfection of
P. falciparum [6]. Shifting to a longer lasting antimal-
arial therapy, such as dihydroartemisinin plus pipera-
quine (DHAp), will extend the chemo-prophylactic
period and thereby help to extend the duration oftransmission suppression during mass treatment inter-
ventions. DHAp has shown better efficacy compared to
AL at clearing asexual blood stage malaria infections,
but while DHA has a similarly short elimination half-
life to AL, piperaquine has a significantly longer ter-
minal elimination half-life of up to 63 days [7, 8].
The results from the previous MTAT trials also sug-
gest that alternatives to the MTAT antimalarial delivery
strategy are needed. One alternative strategy to avoid
some important limitations of MTAT involves treating
all individuals within a specified target area with an ef-
fective antimalarial, irrespective of having a parasite in-
fection identified by an RDT, which would constitute
community-wide mass drug administration (MDA) [9].
There are several potential advantages of using MDA,
especially if coupled with DHAp (MDA-DHAp), over
MTAT-AL. First, RDTs used for diagnosis in the previ-
ous MTAT strategy have been shown to miss up to 50 %
of low-density malaria parasite infections [10], and
thereby leave a substantial reservoir of infection in the
community untreated, which may then sustain contin-
ued transmission. Such individuals with low-density
parasite infections missed by RDTs under the MTAT will
receive treatment under MDA. Second, because MDA-
DHAp may also provide effective chemoprophylaxis
against new infections for the entire target population
(irrespective of RDT result), it is expected to provide a lar-
ger chemoprophylactic and chemo-suppressive effect to
the community than limiting drug administration to only
those individuals testing positive for a malaria infection by
RDT [10, 11]. As a result, MDA-DHAp is potentially more
effective and cost-effective than MTAT, due both to clear-
ance of low-density infections and by prevention of new
infections in the entire population [12].
An alternative to community-wide MDA is focal MDA
(fMDA), which combines aspects of both MTAT and
MDA. fMDA, in this trial, consists of testing all individ-
uals in the community for parasites using RDTs and
treating those that are positive. But in households where
anyone had a positive RDT, all household members are
treated with an effective antimalarial, such as DHAp
(MDA-DHAp), irrespective of each person’s RDT result.
As such, fMDA uses real-time information from RDT
results to focus MDA activities to populations at greatest
risk of having, as well and perhaps acquiring, an infec-
tion. Results of the 2012 MTAT-AL data analysis in this
study site of Southern Province shows considerable clus-
tering of P. falciparum infections identified by RDTs at
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positive, there is a higher chance (than random) that
others in the house are also infected, potentially includ-
ing those with low-density infections missed by RDTs.
Such spatial clustering of infections in other settings
has been well documented [13]. FMDA-DHAp may
therefore provide a substantial advantage to MTAT-AL,
in that it would clear more infections among individ-
uals with parasite infections clustered in households,
even among those with low-density infections missed
by RDTs. Additionally, DHAp given to individuals in
households using fMDA should provide sustained
prophylactic protection for those individuals against
new infections for up to two months, perhaps among
those in the community most at risk of acquiring a new
infection. At the same time, fMDA would limit drug
exposure to those most at risk.
MDA and fMDA using DHAp represent two poten-
tial strategies to achieve greater clearance of human in-
fection and reduction in the parasite reservoir, and
both provide longer chemoprophylactic protection
against new infections. The primary aim of this study is
to quantify the relative effectiveness of MDA and
fMDA with DHAp against no mass treatment for redu-
cing P. falciparum parasite prevalence, confirmed out-
patient malaria case incidence, and monthly infection
incidence in areas stratified by high and low malaria
transmission. It is hypothesized that two rounds of
fMDA and MDA with DHAp will be significantly more
effective than no mass treatment (standard of care) at
reducing these health outcomes. A secondary objective
of this study is to compare the cost and cost-
effectiveness of the fMDA and MDA strategies with
DHAp compared to no mass treatment.
Other outcomes related to the quality of program
implementation will also be measured during this
study to help understand why the MDA and fMDA
with DHAp interventions were, or were not, found to
be effective in this setting. These outcomes include:
participant adherence of taking a full course of DHAp
by the fMDA and MDA interventions; clearance of
asexual stage parasites at day seven following the ad-
ministration of DHAp; population coverage of the
fMDA and MDA interventions in the study areas; and
community acceptability of participating in the fMDA and
MDA interventions. Measurement for these outcomes is
summarized in the Methods/Design section below, with
further details provided in the Additional file 1.
Methods/design
Study site
The study will be conducted in Southern Province Zambia
in districts along Lake Kariba, including Gwembe,
southern Kalomo, Siavonga, and Sinazongwe (Fig. 1).The population of this area was estimated at just over
330,000 living in roughly 56,000 households in 2011,
based on a complete census of the study area con-
ducted during the previous MTAT-AL trial, plus an up-
dated census conducted for this trial in 2014. All
households in the study area were enumerated using a
geographic information system (GIS) prior to February
2014.
The area is primarily composed of the Tonga ethnic
group. Livelihood typically consists of fishing and farming.
While there are towns in the study area, the majority of
the area is rural. The health system throughout the study
area consists primarily of public sector health facilities,
with health facility catchment areas (HFCAs) typically
covering 500 to 1,500 households. All HFCAs were
mapped and geographically defined prior to this study.
Malaria transmission in this area is low to moderate,
with malaria parasite prevalence ranging from less than
1 % in some areas to more than 25 % in other areas. The
high malaria transmission season in the study area
follows the rainy season and lasts from January to May.
Results from the 2012 MTAT-AL intervention identified
two distinct areas of malaria transmission intensity, with
higher transmission areas along the low-lying shores of
Lake Kariba, and lower transmission areas inland from
Lake Kariba.
There are current efforts to maintain high vector
control coverage in the study area, with household
coverage of LLINs estimated to be between 60 and
80 %. Additionally, a comprehensive IRS campaign to
cover all households in the study area was conducted
between November 2014 and January 2015, using the
highly effective insecticide Actellic.
Interventions
Dihydroartemisinin plus piperaquine
DHAp is the study drug used in this trial to treat
P. falciparum parasite infections. DHAp was recently
approved as the alternate first-line treatment in Zambia for
uncomplicated malaria [14]. The DHAp used in this trial
was manufactured by (Sigma Tau, Gaithersburg, Maryland,
USA) and is branded as Eurartesim®. Eurartesim® is the
only Stringent Regulatory Authority (SRA) approved
DHAp product on the international market at this time.
All individuals meeting the inclusion and exclusion
criteria to receive DHAp will be offered an age-
appropriate course of the drug, according to the
manufacturer’s recommendations and the national
guidelines. DHAp dosing will be age-based (age-based
dosing table provided in Additional file 1: Table S1).
Based on the treatment guidelines for uncomplicated
malaria set forth by the manufacturer and the WHO,
a target dose of 4 mg/kg/day dihydroartemisinin and
18 mg/kg/day piperaquine for three days, with a
Fig. 1 Map of the study area, divided into 60 health facility catchment areas that serve as the unit of randomization
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dihydroartemisinin and 16 and 26 mg/kg/day pipera-
quine, will be used (please see Additional file 1: Table
S1 for the age-based dosing guidelines used for ad-
ministering DHAp) [4].Community-wide mass drug administration with
dihydroartemisinin plus piperaquine
Under coordination with the Zambia NMCC, two
rounds of MDA with DHAp are being implemented in
December 2014 (end of dry season) and February 2015
(beginning of rainy season) in selected study site
HFCAs. Spacing of the rounds was determined by the
manufacturer recommendation of not receiving more
than two courses of DHAp within two months [4]. Each
round of the MDA-DHAp intervention consists of test-
ing all individuals with an RDT, sharing the result of
the RDT, and then offering an age-appropriate thera-
peutic dose of DHAp, irrespective of the RDT test re-
sult, among those consenting individuals meeting the
inclusion criteria to receive DHAp, as outlined below
and in Fig. 2. All consenting women in the MDA inter-
vention not in the first trimester of pregnancy are of-
fered DHAp.Household-level focal mass drug administration with
dihydroartemisinin plus piperaquine
Under coordination with the Zambia NMCC, two rounds
of fMDA with DHAp are being implemented in December
2014 (end of dry season) and February 2015 (beginning of
rainy season) in selected study site HFCAs. Each round of
the fMDA-DHAp intervention consists of testing all indi-
viduals with an RDT and then sharing the result of the
RDT. An age-appropriate therapeutic dose of DHAp is
offered to all consenting individuals meeting the inclusion
criteria to receive DHAp, as outlined below and in Fig. 3.
Among all other consenting eligible individuals in the
household where a positive RDT result occurred among
any member, an age-appropriate therapeutic dose of
DHAp is offered, irrespective of the RDT test result of that
individual. All consenting women in the fMDA interven-
tion not in the first trimester of pregnancy are offered
DHAp in accordance with the fMDA process just
outlined.
Directly observed treatment of dihydroartemisinin and
piperaquine in the focal mass drug administration and
mass drug administration intervention rounds
A modified directly observed treatment (DOT) will be
used to maximize adherence with the prescribed
Fig. 2 Participant flow chart to determine antimalarial treatment regimen under MDA-DHAp. Women of reproductive age (WRA): those 15
to 49-years-old; RDT: rapid diagnostic test; HF: health facility; MDA: mass drug administration; DHAp: dihydroartemisinin plus piperaquine
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in the MDA intervention and all individuals in house-
holds with a member with a positive RDT in the
fMDA intervention. At the community level, DHAP
will be given by DOT on the first day of the household
visit to all household members by the campaign team
testing pairs. The second day of the treatment will not
be given by DOT by campaign teams, but will be
asked on the final day of treatment by an adherence
monitoring officer working with the campaign teams.
These adherence officers will make the second house-
hold visit to administer DOT for the third treatment
dose, ask about adherence for the second dose, ob-
serve and count the treatment packets for the
remaining pills, and provide additional instruction on
full compliance if needed.Fig. 3 Participant flow chart to determine antimalarial treatment regime
to 49-years-old; RDT: rapid diagnostic test; HF: health facility; MDA: massInclusion and exclusion criteria of individuals participating
in the intervention
Figures 2 and 3 present an overview of the MDA-DHAp
and fMDA-DHAp inclusion and exclusion criteria. Chil-
dren younger than three-months-old will be excluded
from receiving DHAp, according to the manufacturer
recommendations. Women in their first trimester of
pregnancy will not be offered DHAp in the MDA or
fMDA interventions. Instead these young children and
pregnant women will be offered the appropriate dose of
antimalarial treatment, according to the national treat-
ment guidelines, if found to have a positive RDT.
Pregnancy status during the first trimester will be de-
termined among women ages 12 to 49 years through
direct questioning, and by offering a urine human
chorionic gonadotropin rapid pregnancy test at then under fMDA-DHAp. Women of reproductive age (WRA): those 15
drug administration; DHAp: dihydroartemisinin plus piperaquine
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or reporting longer than five weeks since last menstru-
ation. All consenting women in the MDA and fMDA
interventions with a negative RDT deemed to be in the
first trimester of pregnancy will receive no malaria
treatment. All consenting women deemed to be in their
first trimester of pregnancy with a positive RDT will re-
ceive the recommended standard of care treatment for
uncomplicated malaria in Zambia among women in
their first trimester of pregnancy, which consists of
age-appropriate treatment with oral quinine for seven
days.
All individuals with suspected severe malaria or other
severe illness (including symptoms of severe anemia,
prostration, impaired consciousness, respiratory distress,
convulsions, circulatory collapse, abnormal bleeding,
jaundice, and passing black or brown (dark) urine) will
be referred to the nearest health facility for treatment,
and will not be included in the MDA or fMDA interven-
tions or associated research.
Community mobilization
MDA requires high levels of participation and adherence
to the full treatment course to be as effective as possible.
To encourage participation, several activities were con-
ducted in advance of and during the treatment campaigns
in order to broaden and strengthen community awareness.
First, information about the campaigns, the treatments,
and the process were shared through the Ministry of
Health and Ministry of Community Development, Mother
and Child Health structures, including among community
health workers to begin discussions at local levels. Second,
community sensitization meetings were held throughout
campaign areas across nine districts to inform leaders at
the district level, including district councilors, religious
leaders, and lead educators, and at the chiefdom level,
with special outreach to chiefs, village headmen, local
community health workers, and community members
gathered for village entry meetings. Information, educa-
tion, and communication materials were developed with
the Zambia NMCC on malaria and pretested in campaign
areas, containing behavior change communication mes-
sages for community members and community leaders.
These were translated into the local language and distrib-
uted at these community sensitization meetings. Third,
radio spots were developed and aired in the local language
in target areas, along with a series of radio group episodes
in which community members engaged with campaign
health experts to learn about the program and discuss the
benefits of participation.
Standard of care and control group
Standard of care in Zambia, including the study area in
Southern Province, consists of identification of malariainfections and clinical cases through passive case detec-
tion at local health facilities or community health
workers. Zambian national policy stipulates that indi-
viduals seeking care for a fever be given a malaria diag-
nostic test by RDT or microscopy. Individuals with
confirmed malaria are then treated with the first-line
antimalarial in Zambia, which is AL. When no diagnos-
tic test is available at a health facility, a clinical diagno-
sis is made based on signs and symptoms, and
treatment follows the identical protocol as with RDT-
confirmed malaria cases. Standard of care does not
include any kind of active surveillance for malaria para-
site infection or mass treatment of the population with
antimalarials.
Study design
A CRCT will be used to evaluate the impact of two rounds
of the MDA-DHAp or fMDA-DHAp (the two interven-
tion arms) at reducing malaria parasite infection preva-
lence and incidence, as well as malaria-related morbidity,
compared to a control group receiving standard of care.
Communities, or clusters, are defined by HFCAs and
serve the unit of randomization. A total of 60 health facil-
ities and their catchment areas are included in the study.
Stratification
As the impact of the MDA and fMDA interventions are
expected to vary across malaria transmission strata, the
60 HFCAs included in the study have been stratified into
high and low transmission strata. To do this, parasite
prevalence in each HFCA was estimated with a kriged
continuous surface of parasite prevalence from data
from the baseline 2014 parasite survey. Catchments were
then ranked from highest to lowest parasite prevalence.
The top 30 HFCAs were included in the high transmis-
sion strata, while the bottom 30 were included in the
low transmission strata; the resulting cut point between
the high and low transmission strata was approximately
10 % parasite infection prevalence.
Randomization sequence generation and allocation
concealment
Pre-existing maps of HFCAs were used to classify
households as belonging to a specific HFCA, which
serve as the unit of randomization. To ensure balance
across large and small HFCAs, which could potentially
affect the quality of program implementation and
other related unobserved confounding factors, HFCAs
were characterized as having either a large or small
population catchment size. This classification was
based on a cut-point obtained from the mean popula-
tion catchment size across the 60 HFCAs. Within the
high and low transmission strata and the large and
small population catchment size classifications, the
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to the fMDA-DHAp, MDA-DHAp, or control group.
As a result of this process and the stratification out-
lined above, the 60 total HFCAs are split into 10
HFCAs per treatment group (MDA, fMDA, and con-
trol) in the high transmission strata (n = 30 HFCAs),
and 10 HFCAs per treatment group (MDA, fMDA,
and control) in the low transmission strata (n = 30
HFCAs).
After allocation, the appropriate intervention will be
implemented in the entire catchment area according to
treatment group assignment. Allocation of study arms
will not be blinded to the deliverers of the intervention
or to the main investigators, as delivery of the interven-
tion precludes the possibility of allocation concealment.
However, data collectors in the follow-up parasite
prevalence survey, as outlined below, will be blinded to
allocation. All primary analyses will also be blinded to
analysts by the use of concealed code for the study arm
variables in the final dataset.
Primary outcome measures
Primary outcomes used to measures the impact of the
MDA-DHAp and fMDA-DHAp interventions, as com-
pared to a control of standard of care, are:
1. Parasite prevalence during the high transmission
season among children < six-years-old: defined as the
proportion of children < six-years-old (≥three
months to < six-years-old) with P. falciparum
infection (based on both RDT and PCR) out of all
children < six-years-old tested within the 2014 and
2015 cross-sectional parasite surveys.
2. P. falciparum infection incidence rate among
individuals ≥ three-months-old: defined as the
number of individuals ≥ three-months-old with a
new P. falciparum infection (based on PCR) divided
by the total person-time observed among a cohort
of individuals ≥ three-months-old followed up on for
a 12-month-period.
3. Total and confirmed outpatient (OPD) malaria case
incidence and inpatient (IPD) malaria case incidence
among all ages: defined as the number of OPD and
IPD malaria confirmed and suspected cases per
person per year, as ascertained from the routine
rapid reporting system; facility catchment population
size estimates will be used for the exposure
denominator.
4. RDT positivity: defined as the proportion of all
individuals tested by RDT at each round of the
fMDA and MDA interventions (and among a
contemporaneous sample in the control group),
with a positive RDT, among the population of
individuals ≥ three-months-old.Data collection procedures for measurement of outcomes
For all data collection procedures, written informed
consent will be obtained from each participant prior to
study enrollment in the trial.
Diagnosis of Plasmodium falciparum infections
P. falciparum parasite infections will be measured using
RDTs, microscopy, and PCR, depending on the study
outcome, as described below. The RDTs used in this
trial are manufactured by (Standard Diagnostics Inc.,
Gyeonggi-do, Republic of Korea) under the brand name
SD Bioline Malaria Antigen P.f, which detects the
Histidine-rich protein 2 (HRP-2) antigen of P. falcip-
arum. This RDT is approved by the WHO, Global
Fund, and the Zambian Ministry of Health. RDTs are
used across all data collection methods in this trial, in-
cluding the parasite surveys, longitudinal cohort, fMDA
and MDA rounds, and at health facilities in the study
area. Detection of malaria parasite infections from mi-
croscopy is based on thick smears. Thick blood smears
for microscopy will be used in the parasite surveys and
the longitudinal cohort. PCR will be performed from
capillary blood collected on dried blood spots (DBS) on
filter paper, to identify low-density asexual and sexual
stage parasite infections, as part of the parasite surveys
and the longitudinal cohort.
Baseline and follow-up household parasite surveys
A cross-sectional survey of households in the high trans-
mission season (April to May) in 2014, and again in
2015, will be conducted to obtain an unbiased sample of
children under six-years-old (excluding those under
one-month-old) for measuring primary outcome one
(parasite prevalence). All children under six-years-old
that slept in the house the night before the survey will
be included in the sample. A complete enumeration and
geo-referencing of all households in the study area
serves as the sampling frame. To mitigate contamination
between exposure groups (MDA, fMDA, and control) in
the household sampling frame, sampling buffers of at
least 1.5 km were derived for all HFCAs using GIS, in
order to maintain an adequate distance between house-
holds in HFCAs with different exposure assignments
(resulting in a gap of at least 3 km between sampled
households in different HFCAs). A simple random sam-
ple of 47 households was then drawn within each of the
60 HFCAs (equal allocation sampling), to obtain the
total sample size of 2,820 households in the 2014 base-
line survey, after restricting the sampling frame for sam-
pling buffers in GIS. The same sampling procedure will
be used for the follow-up parasite survey in 2015.
Selected households during each survey round will be
visited by trained survey data collectors that will
administer a standardized survey questionnaire using
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tor Survey (MIS) questionnaire [15]. Capillary blood
from a finger prick from all children in selected house-
holds will be collected for detection of a malaria para-
site infection by RDT, microscopy, and PCR. Children
found to have a positive RDT will be treated for their
infections with AL as per the Zambia National Malaria
Treatment Guidelines [14].Longitudinal cohort
P. falciparum infection incidence will be measured by
following a cohort of individuals aged three-months-
old and older (and not pregnant) for measuring
primary outcome indicator two, the P. falciparum in-
fection incidence rate (Fig. 4). Individuals within each
HFCA and treatment group, within the high and low
transmission strata, will be preselected from those reg-
istered in the household roster in selected households
during the baseline household parasite survey between
April and May 2014. Enrollment of individuals will
start during round one (November 2014) of the fMDA
and MDA interventions, and concurrently among indi-
viduals during round one in control areas visited for
assessing RDT positivity.Fig. 4 Flow chart for cohort enrollment and follow-up visit for both high and lo
plus piperaquine; MDA: Mass drug administration; fMDA: focal mass drug admCapillary blood from a finger prick from all enrolled
participants will be collected at the time of enrollment
for detection of a malaria parasite infection by RDT,
microscopy, and PCR. For individuals enrolled into
the cohort from the round one of MDA HFCAs, all
will be offered an appropriate dose of DHAp the same
as those in the MDA study, irrespective of RDT result.
For individuals enrolled into the cohort from the
round one fMDA HFCAs, those testing positive by
RDT or in households with any member testing posi-
tive by RDT will be offered an appropriate dose of
DHAp the same as those in the fMDA study. Individ-
uals enrolled into the cohort in control HFCAs testing
positive by RDT will receive age and weight appropri-
ate formulations of AL, as per standard of care guide-
lines [14].
Enrolled individuals within the MDA, fMDA, and con-
trol HFCAs will then be followed up on every four
weeks from enrollment date for collection of blood for
an RDT, microscopy, and DBS for PCR, until the study’s
conclusion in November 2015. Any individual testing
positive for circulating malaria antigen by RDT during
any visit after enrollment will receive treatment of age-
and weight-appropriate doses of AL, as per standard of
care guidelines [14].w transmission strata. AL: Artemether-lumefantrine; DHAp: Dihydroartemisinin
inistration; RDT: Rapid diagnostic test; DBL: Dried blood spots
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malaria cases
Data on aggregate clinical and laboratory confirmed mal-
aria cases and total outpatients seen are submitted on a
weekly basis, through a standardized forma on data-
enabled cell phones, using the District Health Information
System 2 (DHIS2) rapid reporting system, from all 60
health facilities in the study area. Data from this source
are accessible via a web server with password protection.
This system was established in 2011 and 2012 and has
been running in the catchment areas ever since. Time
series data by facility week will be collated from this sys-
tem to provide a passive incidence-based data set for
evaluation of the impact of the MDA and fMDA interven-
tions, as compared to a control of no mass treatment, on
primary outcome three. Confirmed and total case counts
will be standardized by the estimated mid-year popula-
tions of each HFCA.Rapid diagnostic test positivity during campaign rounds
As described above under the MDA and fMDA interven-
tion descriptions, all individuals aged three-months-old
and older in these HFCAs will be tested by RDT for de-
tecting malaria parasite infections; this will then be used
for ascertaining primary outcome four (RDT positivity) in
each HFCA. RDT positivity in control areas during each
of the two rounds of the MDA and fMDA interventions in
2014, and again in 2015, will be obtained through compar-
ing RDT positivity among individuals tested as part of the
monthly control cohort during the months when the
MDA and fMDA rounds occur.Cost data
Cost data collection will be coupled with the study in order
to provide numerator estimates for cost-effectiveness
calculations. Cost data collection will be provider focused
and will not require collection of data from intervention
participants or research subjects. Data on the cost of inputs
to the intervention will be collected using a review of pro-
gram records and reports, invoices, budgets, expenditure
reports, and interviews with intervention implementers.
Interviews will be focused on resource use during the im-
plementation of the study interventions. Where direct
estimates of unit costs for inputs are not available through
the above methods, data on costs will be supplemented
with secondary source data, such as is available from the
WHO-CHOICE database, the National Bank of Zambia,
the World Bank, the International Monetary Fund, or
other published literature. Economic costs will be
estimated, meaning that costs from donated inputs will
also be valued.Sample size and statistical power
The maximum number of cluster units available was
60, split evenly with 10 clusters per MDA, fMDA, and
control groups in the high and low transmission strata.
Sample size was derived using a formula for CRCTs
developed by Hayes and Moulton [16]. Sample sizes are
estimated to assess statistical differences comparing the
four primary outcomes for the MDA group against no
intervention (control), and for the fMDA group against
no intervention (control).Baseline and follow-up household parasite surveys
High transmission strata The coefficient of variation
(CV) was estimated using data from a previous study of
the 2012 MTAT-AL in the study area (CV = 0.31).
Based on the number of clusters available in the high
transmission strata (n = 10 in each of the three treat-
ment groups, total of 30 clusters), a statistical power of
80 %, a probability of committing a type two error of
5 % (one-tailed test), and simple random sampling used
to obtain the sample of children in each household sur-
vey, a sample size of 39 children under-years-old per
HFCA per treatment group will be needed to detect
12 % absolute detectable difference in parasite preva-
lence between any two groups, from a baseline of 30 %
(a 40 % relative difference, going from 30 to 18 % para-
site prevalence). This detectable difference equates to a
crude odds ratio of 0.51. With survey non-response as-
sumed to be 20 %, a sample size of 470 children per
treatment group (47 children per cluster), totaling
1,410 children under six-years-old per survey round
will be sought (Additional file 1: Table S2). This sample
size equates to a sample size of 1,410 households sam-
pled per survey round.Low transmission strata Based on the number of clus-
ters available in the low transmission strata (n = 10 in
each of the three treatment groups, total of 30 clusters),
the observed CV (CV = 0.41), a statistical power of
80 %, a probability of committing a type two error of
5 % (one-tailed test), and simple random sampling used
to obtain the sample of children in each household sur-
vey, a sample size of 39 children under six-years-old
per HFCA per treatment group will be needed to detect
6 % absolute detectable difference in parasite preva-
lence between any two groups from a baseline of 10 %
(a 60 % relative difference going from 10 to 4 % para-
site prevalence). This detectable difference equates to a
crude odds ratio of 0.38. With survey non-response
assumed to 20 %, a sample size of 470 children per
treatment group (47 children per cluster), totaling
1,410 children under six-years-old per survey round
will be sought (Additional file 1: Table S2). This sample
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pled per survey round.
Longitudinal cohort
High transmission strata The CV for infection inci-
dence was based on estimates of OPD confirmed case
incidence for HFCAs for 2012 (CV = 0.50). Based on
the 30 HFCAs available in the high transmission strata,
a statistical power of 80 %, a probability of committing
a type two error of 5 % (one-tailed test), a sample size
of 25 individuals aged three-months-old and older per
HFCA (cluster) per treatment group will be needed to
detect an absolute detectable difference in 12-month
cumulative parasite infection incidence between any
two groups from an assumed baseline of 1.8 infections
per person per year to 0.91 infections per person per
year (a 49 % relative reduction). With a loss to follow-up
rate assumed to be 33 %, a sample size of 375 individuals
per treatment group (38 per HFCA) will be enrolled and
followed up on monthly, totaling 1,125 individuals aged
three-months-old and older enrolled in the cohort
study in the high transmission strata (Additional file 1:
Table S3).
Low transmission strata The CV for infection incidence
was based on estimates of OPD confirmed case incidence
for HFCAs in 2012 (CV = 0.50). Based on the 30 HFCAs
available in the low transmission strata, a statistical power
of 80 %, a probability of committing a type two error of
5 % (one-tailed test), a sample size of 27 individuals aged
three-months-old and older per HFCA (cluster) per treat-
ment group will be needed to detect absolute detectable
difference in parasite infection incidence between any two
groups from an assumed baseline of 0.6 infections per per-
son per year to 0.28 infections per person per year (a 53 %
relative reduction). With a loss to follow-up rate assumed
to be approximately 33 %, a sample size of 375 individuals
per treatment group (38 per cluster) will be enrolled and
followed up on monthly, totaling 1,125 individuals en-
rolled in the cohort study in the low transmission strata
(Additional file 1: Table S3).
Rapid diagnostic test positivity during campaign rounds
It is estimated based on the population sizes of the
MDA and fMDA HFCAs, a sample size exceeding
50,000 individuals aged three-months-old and older in
each group (approximately 5,000 per HFCA) will be
achieved. As described above, a sample size of 750 indi-
viduals aged three-months-old and older in the cohort
in the control HFCAs will provide contemporaneous
measure of RDT positivity in areas without intervention
rounds (n = 375 individuals in the high transmission
strata and 375 individuals in the low transmissionstrata). This sample size in areas of high transmission will
provide 80 % statistical power to detect a 33 % difference
(an absolute decrease from 30 to 20 %; odds ratio of 0.58)
in RDT positivity between the control group and either of
the MDA groups, assuming a baseline prevalence of 30 %,
a CV = 0.31, 10 HFCAs in each treatment group, and a
probability of committing a type two error of 5 % (one-
tailed test). This sample size in areas of low transmission
will provide 80 % statistical power to detect a 50 % differ-
ence (an absolute decrease from 10 to 5 %; odds ratio of
0.47) in RDT positivity between the control group and ei-
ther of the MDA groups, assuming a baseline prevalence
of 10 %, a CV = 0.41, 10 HFCAs in each treatment group,
and a probability of committing a type two error of 5 %
(one-tailed test).
Statistical analysis plan
The primary analysis for estimating the treatment effect
between MDA, fMDA, and control HFCAs for primary
outcome one (parasite prevalence) and two (parasite infec-
tion incidence rates) will be based on intention to treat at
the individual level for infections measured by RDT and
PCR. The analysis of parasite prevalence will use a logistic
or log binomial model, while the analysis for infection in-
cidence will use a Poisson or negative binomial model.
Models will include a random intercept at the HFCA level
(randomization unit), fixed effect for intervention expos-
ure, time period (pre- and post-intervention), plus other
potential confounding factors. Standard errors will be esti-
mated, with the addition of repeated measures among
individuals.
Data for total and confirmed OPD and IPD malaria
case incidence (outcome three) among all ages will be
analyzed on an intention-to-treat basis. Routine data on
case counts will be analyzed using a Poisson or negative
binomial model, with random intercepts at the HFCA
level. The models will include a fixed effect for study
arm and time period (pre- and post-intervention), plus
other potential confounding factors.
Differences in prevalence measures (RDT positivity) at
each round will be assessed using an X2 test, as well as
logistic regression models to account for potential con-
founding factors, on an intention-to-treat basis. Logistic
models will include a random intercept for HFCA, as well
as fixed effects for other potential confounding factors.
Trends in parasite prevalence across rounds, with the in-
clusion of the control group, will then allow rapid assess-
ment of the effect of the fMDA and MDA interventions
over time, after removing the seasonality effect.
Standard methods for collecting cost data for the spe-
cific components of the work will be used to then
summarize intervention costs. Cost-effectiveness calcula-
tions will be undertaken utilizing cost data collected as
above, as well as the findings of the study evaluation on
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effectiveness outcome will be the calculation of the incre-
mental cost effectiveness ratios (ICERs) comparing the
cost-effectiveness of MDA to the standard of care, and the
ICER of fMDA alone versus standard of care. Secondary
outcomes will include the ICER of MDA versus fMDA
alone, and the stratified analysis of all three previously
listed outcomes by high and low prevalence settings. Fur-
ther details of the cost and cost-effectiveness analysis are
presented in the Additional file 1.
Quality control and secondary studies
Mass drug administration and focal mass drug
administration intervention coverage
The population coverage of the MDA and fMDA inter-
ventions will be measured in two ways at each interven-
tion round. Operational program coverage is defined as
the proportion of individuals aged three-months-old and
older, and households visited, offered the MDA and fMDA
interventions within the target areas. Effective program
coverage is defined as the proportion of individuals (aged
three-months and older) that agreed to participate in the
MDA and fMDA interventions among all individuals
eligible to participate in the intervention in the target
population.
The operational coverage will be estimated as the
percent of the population that received a visit from the
mass treatment teams to offer the MDA or fMDA in-
terventions, among those eligible for inclusion. This will
be obtained from a combination of MDA and fMDA pro-
gram data and census enumeration data. Additionally, the
proportion of individuals accepting the MDA and fMDA
interventions aged three-months-old and older, among
those eligible for inclusion in the intervention, will provide
an estimate of the effective coverage of each program, as
outlined below. Data for the denominator of individuals
and households targeted for the intervention will be ascer-
tained from the household enumeration for the sampling
frame. Individual, household, and community level factors
associated with coverage will be assessed using mixed ef-
fects logistic regression.
Participant adherence to dihydroartemisinin and
piperaquine
A total of 150 individuals enrolled in the cohort study at
round one, with a positive RDT in the MDA (n = 75) and
fMDA (n = 75) rounds, plus another 150 individuals en-
rolled in the cohort study at round one, with a negative
RDT in the MDA round, will be used to assess the level of
adherence with the prescribed DHAp antimalarial regi-
men. Further details of the primary outcomes, sample
size calculations, data collection methods, and the stat-
istical analysis plan for this sub-study are provided in
the Additional file 1.Plasmodium falciparum parasite clearance following
dihydroartemisinin and piperaquine
A total of 150 individuals enrolled in the cohort study at
round one, with a positive RDT in the MDA (n = 75) and
fMDA (n = 75) rounds, will be used to assess parasite clear-
ance following DHAp. Further details of the primary out-
comes, sample size calculations, data collection methods,
and the statistical analysis plan for this sub-study are pro-
vided in the Additional file 1.Acceptability of dihydroartemisinin and piperaquine in the
community
The assessment of community acceptability of the MDA
and fMDA interventions will be ascertained using a mixed
methods approach. Acceptability of the interventions will
be assessed quantitatively during the baseline and follow-
up parasite surveys among WRA. Focus groups will also
be used to qualitatively assess community perceptions of
the acceptability of the MDA and fMDA interventions,
including community members who consented and partic-
ipated, as well as those who refused. Further details of the
acceptability study are provided in the Additional file 1.Study timeline
Figure 5 shows the timeline for the major activities for
the primary study of evaluating the impact of the MDA
and fMDA interventions on reducing malaria morbidity.
The study started with the randomization of HFCA in
early 2014. The baseline parasite survey was conducted
between April and May of 2014 during the peak malaria
transmission season. The first MDA and fMDA rounds
were conducted between November and December
2014, with round two scheduled for February 2015. The
longitudinal cohort started at the same time as the first
MDA and fMDA round in November 2014; the cohort
will continue monthly follow-up through November
2015. Routine data on confirmed OPD malaria cases
started in January 2014 and will continue through 2015.
The follow-up parasite survey is scheduled to take place
between April and May 2015, during the peak malaria
transmission season.Ethical approval
Ethical approval in Zambia for the primary and second-
ary studies has been obtained from the Research Ethics
Committee (REC) at the University of Zambia (study
reference 007-03-14) and the Zambian Medicines
Regulatory Authority (trial number CT 033/12). Ethical
approval was also obtained from the Tulane Institu-
tional Review Board (IRB; study number 59208573) and
Western IRB (covering PATH-MACEPA; study number
1146551).
Fig. 5 Study timeline for major activities. MDA: mass drug administration; fMDA: Focal mass drug administration; LLIN: Long-lasting insecticide-treated
nets; IRS: Indoor residual spraying; HFCA: Health facility catchment area; HMIS: Health management information system
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In line with the goals of the Zambia National Malaria Stra-
tegic Plan, robust comparisons of the effectiveness and
cost-effectiveness of available mass treatment approaches,
including MDA and fMDA interventions using DHAp, are
needed. Toward that end, this study will assess the relative
effectiveness of two mass treatment approaches at redu-
cing the malaria burden beyond already implemented in-
terventions of LLINs and IRS. The relative effectiveness of
MDA and fMDA with DHAp will be established against a
comparison of no mass treatment (standard of care) in
areas with higher and lower malaria parasite prevalence
using a community randomized control trial. The findings
of this study will provide the Zambia NMCC and their
partners with guidance on the most effective and cost-
effective strategies to further reduce the size of the malaria
parasite reservoir, malaria transmission, and the incidence
of clinical disease in southern Zambia, and will hopefully
show evidence of local transmission interruption.
The strengths of this trial include the fact that a rigorous
study design (a CRCT) will be used to assess the impact of
the MDA and fMDA interventions, as compared to a con-
trol of no mass treatment (standard of care). The study is
also powered to assess differences between each treatment
group (MDA and fMDA) and the control group, within
areas of high and low transmission, with 80 % statistical
power. The study uses robust measures of malaria parasite
infection at the point of contact using RDTs, as well as
PCR, for detecting low-density parasite infections, as part
of the parasite surveys and the longitudinal cohort. The
study also uses multiple methods for measuring malaria-
related outcomes, including malaria parasite infection
prevalence ascertained from a pre- and post-parasite sur-
vey, malaria parasite infection incidence using a longitu-
dinal cohort of individuals selected randomly from within
each HFCA, and confirmed malaria case incidencethroughout the study using routine health management
information system (HMIS) data in the study area. Buffer
areas between contiguous HFCAs with different interven-
tions are being used to limit contamination and misclassifi-
cation bias. Measures of the quality of the implementation
of the MDA and fMDA interventions will be obtained to
help with the interpretation of results; these include MDA
and fMDA population coverage, adherence to DHAp,
parasite clearance after DHAp, community perceptions
and acceptability of the MDA and fMDA interventions,
and multiple measures of operational coverage. Lastly, a
rigorous analysis plan will be followed, for assessing the
impact of each intervention compared to a control group,
while accounting for potential contextual and confounding
factors within random-effect regression models.
Noted weaknesses of this trial include a less than ideal
number of community randomization units (N = 60),
especially when stratified by high (n = 30) and low (n = 30)
transmission strata. The sample size within the high
and low transmission strata will only allow the detec-
tion of approximately a 50 % reduction in parasite
prevalence and infection incidence between interven-
tion groups, with 80 % statistical power; the threat of
a type two error is therefore higher than ideal. The
primary analysis will be based on the intention-to-
treat principle; there is potential for misclassification
of exposure using this approach. Secondary analysis
using a per-protocol approach will be used mitigate
any misclassification of exposure. And lastly, there is
always the potential for error in the measurement of
outcomes, exposure to the interventions, and potential
confounding factors in such a large and complex trial.
We have gone to considerable length to try and
minimize such error through the use of electronic data
capture systems in the field and robust diagnostic
methods.
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The study is ongoing. The baseline parasite survey was
completed in April to May 2014. The first round of the
MDA and fMDA intervention was completed in November
to December 2014; the longitudinal cohort started at the
same time. The second round of the MDA and fMDA
intervention is scheduled for February 2015 (conclud-
ing in mid-March 2015). The follow-up parasite survey
is scheduled for April to May 2015, while monthly lon-
gitudinal follow-up is scheduled to continue through
November 2015.Additional file
Additional file 1: Web appendix containing supporting information.
(DOCX 60 kb)
Abbreviations
AL: Artemether lumefantrine; CRCT: Cluster randomized control trial;
DHA: Dihydroartemisinin; DHAp: Dihydroartemisinin plus piperaquine;
DOT: Directly observed therapy; fMDA: Focal mass drug administration;
HFCA: Health facility catchment area; ICER: Incremental cost effectiveness
ratio; IPD: Inpatient; IRB: Institutional review board; IRS: Indoor-residual
spraying; LLIN: Long-lasting insecticide-treated mosquito net; MDA: Mass
drug administration; NMCC: National Malaria Control Center;
OPD: Outpatient; RDT: Rapid diagnostic test; REC: Research ethics committee;
PCR: Polymerase chain reaction; WHO: World Health Organization;
WRA: Women of reproductive age.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
TPE helped conceive the study aims, research questions, and study design,
helped undertake the study, and contributed to the statistical issues in the
trial design and statistical analysis plan. KS designed the training materials
and performed the training, and helped undertake the study. TF designed
the training materials and performed the training, helped conceive the study
aims, research questions, and study design, contributed to the statistical
analysis, and helped undertake the study. VC helped undertake the study.
MK commented on the protocol. BH helped undertake the study. HM led
the laboratory procedures for the study. AB helped conceive the study aims,
research questions, and study design, contributed to the statistical analysis,
and helped undertake the study. JY helped conceive the study aims,
research questions, and study design, and contributed to the statistical
analysis. JK contributed to the statistical analysis. RWS obtained funding for
this study and helped conceive the study aims, research questions, and
study design. JMM obtained funding for this study, helped conceive the
study aims, research questions, and study design, is responsible for
undertaking the study, helped develop training materials, and contributed to
the statistical issues in the trial design and statistical analysis plan. All authors
read and approved the final manuscript.
Acknowledgements
We express our gratitude to the study respondents in Southern Providence
for participating in this study. We also express our gratitude to the Zambia
Ministry of Health and Ministry of Community Development, Mother and
Child Health. We also thank the Bill & Melinda Gates Foundation for their
financial support.
This study was funded by the Bill and Melinda Gates Foundation. Tulane
University was funded by a subcontract from PATH-MACEPA under funding
for this study by the Bill & Melinda Gates Foundation (OPP1089412). The Bill
& Melinda Gates Foundation reviewed and commented on the draft study
protocol.Author details
1Center for Applied Malaria Research and Evaluation, Tulane University
School of Public Health and Tropical Medicine, 1440 Canal Street, Suite 2200,
New Orleans, LA, USA. 2PATH-Malaria Control and Elimination Partnership in
Africa (MACEPA), National Malaria Control Centre, Chainama Hospital College
Grounds, Lusaka, Zambia. 3Institute for Medical Research and Training,
University Teaching Hospital, Lusaka, Zambia. 4National Malaria Control
Centre, Zambia Ministry of Health, Chainama Hospital, Lusaka, Zambia.
5Malaria Elimination Initiative, Global Health Group, University of California
San Francisco, 550 16th Street, San Francisco, CA, USA. 6PATH-MACEPA, 2201
Westlake Avenue, Seattle, WA, USA.
Received: 13 February 2015 Accepted: 14 July 2015
References
1. Zambia Ministry of Health. National Malaria Control Programme Strategic
Plan for FY 2011–2015: Consolidating malaria gains for impact. Lusaka:
Zambia Ministry of Public Health; 2011
2. Chizema-Kawesha E, Miller JM, Steketee RW, Mukonka VM, Mukuka C,
Mohamed AD, et al. Scaling up malaria control in Zambia: progress and
impact 2005–2008. Am J Trop Med Hyg. 2010;83(3):480–8.
3. Larsen DA, Bennett A, Silumbe K, Hamainza B, Yukich JO, Keating J, et al.
Population-wide malaria testing and treatment with rapid diagnostic tests
and artemether-lumefantrine in southern zambia: a community randomized
step-wedge control trial design. Am J Trop Med Hyg. 2015;92(5):913–21.
4. World Health Organization (WHO). Guidelines for the treatment of malaria.
2nd ed. Geneva: WHO; 2010.
5. Cook J, Xu W, Msellem M, Vonk M, Bergstrom B, Gosling R, et al. Mass
screening and treatment on the basis of results of a Plasmodium
falciparum-specific rapid diagnostic test did not reduce malaria incidence in
Zanzibar. J Infect Dis. 2015;211(9):1476–83.
6. Ashley EA, Stepniewska K, Lindegardh N, McGready R, Annerberg A,
Hutagalung R, et al. Pharmacokinetic study of artemether-lumefantrine
given once daily for the treatment of uncomplicated multidrug-resistant
falciparum malaria. Trop Med Int Health. 2007;12(2):201–8.
7. Zani B, Gathu M, Donegan S, Olliaro PL, Sinclair D. Dihydroartemisinin-
piperaquine for treating uncomplicated Plasmodium falciparum malaria.
Cochrane Database Syst Rev. 2014;1:CD010927.
8. Sawa P, Shekalaghe SA, Drakeley CJ, Sutherland CJ, Mweresa CK, Baidjoe
AY, et al. Malaria transmission after artemether-lumefantrine and
dihydroartemisinin-piperaquine: a randomized trial. J Infect Dis.
2013;207(11):1637–45.
9. Poirot E, Skarbinski J, Sinclair D, Kachur SP, Slutsker L, Hwang J. Mass drug
administration for malaria. Cochrane Database Syst Rev. 2013;12:CD008846.
10. Okell LC, Bousema T, Griffin JT, Ouedraogo AL, Ghani AC, Drakeley CJ.
Factors determining the occurrence of submicroscopic malaria infections
and their relevance for control. Nat Commun. 2012;3:1237.
11. McMorrow ML, Aidoo M, Kachur SP. Malaria rapid diagnostic tests in
elimination settings–can they find the last parasite? Clin Microbiol Infect.
2011;17(11):1624–31.
12. von Seidlein L, Greenwood BM. Mass administrations of antimalarial drugs.
Trends Parasitol. 2003;19(10):452–60.
13. Bejon P, Williams TN, Liljander A, Noor AM, Wambua J, Ogada E, et al. Stable
and unstable malaria hotspots in longitudinal cohort studies in Kenya. PLoS
Med. 2010;7(7):e1000304.
14. Zambia Ministry of Health. Guidelines on diagnosis and treatment of
malaria in Zambia, 4th ed. Lusaka: Zambia Ministry of Public Health; 2014.
15. RBM. Guidelines for Core Population-based Indicators Calverton, Maryland, Roll
Back Malaria, MEASURE Evaluation, World Health Organization, UNICEF: 2009.
16. Hayes RJ, Moulton LH. Cluster randomised trials. London, UK: Chapman &
Hall/CRC Biostatistics Series; 2009.
